Shares of Sun Pharma Industries Ltd ended 1.25% lower on 1st December, even as the firm announced the launch of its global innovative drug, Ilumya (Tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis.

Sun Pharma said Ilumya is a novel biological treatment. It has been widely endorsed by dermatologists in the US and other countries for many years. The drug is considered a safe and effective therapy for moderate-to-severe plaque psoriasis. Managing director Kirti Ganorkar noted that the drug is already available in 35 countries. It has shown strong, long-lasting skin clearance soon after treatment begins.

The company’s India study involved 15 patients with moderate-to-severe plaque psoriasis. They received three subcutaneous doses of Tildrakizumab over 16 weeks and were monitored for 28 weeks. The results showed 75% skin clearance in 62.3%, 83.3%, and 93.9% of patients at Weeks 12, 16 and 28, respectively. Additionally, 90% skin clearance was achieved in 26.3%, 50% and 78.1% of patients over the same periods. The company said significant improvements were also seen in quality-of-life scores.

Sun Pharma added that Ilumya is the first IL-23 inhibitor to complete five years of study. This conclusion is based on pooled data from two Phase 3 extension trials. It said patients with moderate-to-severe plaque psoriasis need long-term therapies that remain effective. Current data indicate that Ilumya is a reliable long-term option.

At 3:30 PM, shares of Sun Pharmaceutical ended 1.23% lower at Rs 1,809 on NSE.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!